BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu G, Wu J, Pan X, Liu B, Yao Z, Guo Y, Shi X, Ding Y. Racial disparities in alpha-fetoprotein testing and alpha-fetoprotein status associated with the diagnosis and outcome of hepatocellular carcinoma patients. Cancer Med. 2019;8:6614-6623. [PMID: 31517445 DOI: 10.1002/cam4.2549] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Wu G, Wu J, Pan X, Liu B, Yao Z, Guo Y, Shi X, Ding Y. Racial disparities in alpha-fetoprotein testing and alpha-fetoprotein status associated with the diagnosis and outcome of hepatocellular carcinoma patients. Cancer Med. 2019;8:6614-6623. [PMID: 31517445 DOI: 10.1002/cam4.2549] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
2 Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. Cells 2020;9:E1370. [PMID: 32492896 DOI: 10.3390/cells9061370] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
3 Guo Z, Wang J, Li L, Liu R, Fang J, Tie B. Value of miR-1271 and glypican-3 in evaluating the prognosis of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization. World J Clin Cases 2020; 8(16): 3493-3502 [PMID: 32913856 DOI: 10.12998/wjcc.v8.i16.3493] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Rajappa S, Rau KM, Dattatreya PS, Ramaswamy A, Fernandes P, Pruthi A, Cheng R, Lukanowski M, Huang YH. Second-line treatment of advanced hepatocellular carcinoma: Time for more individualized treatment options? World J Hepatol 2022; 14(6): 1074-1086 [DOI: 10.4254/wjh.v14.i6.1074] [Reference Citation Analysis]
5 Karbownik A, Miedziaszczyk M, Grabowski T, Stanisławiak-Rudowicz J, Jaźwiec R, Wolc A, Grześkowiak E, Szałek E. In vivo assessment of potential for UGT-inhibition-based drug-drug interaction between sorafenib and tapentadol. Biomed Pharmacother 2020;130:110530. [PMID: 32712531 DOI: 10.1016/j.biopha.2020.110530] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Li X, Liu L, Li N, Jia Q, Wang X, Zuo L, Long J, Xue P, Sun Z, Zhao H. Metabolomics based plasma biomarkers for diagnosis of oral squamous cell carcinoma and oral erosive lichen planus. J Cancer 2022;13:76-87. [PMID: 34976172 DOI: 10.7150/jca.59777] [Reference Citation Analysis]